A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Bayesian Adaptive Randomization Design, Dose Response Study of the Efficacy of E2006 in Adults and Elderly Subjects With Chronic Insomnia
Overview
- Phase
- Phase 2
- Intervention
- E2006
- Conditions
- Chronic Insomnia
- Sponsor
- Eisai Inc.
- Enrollment
- 291
- Primary Endpoint
- Probability of Having Utility Function Greater Than (>) 1 Based on Bayesian Analysis
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
This is a multicenter, multiple dose, randomized, double-blind, placebo-controlled, parallel-group, Bayesian adaptive, dose response study in subjects with chronic insomnia. Subjects will be randomized to 1 of 6 doses of E2006 (1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg) or placebo.
Detailed Description
The study will have 2 phases, Prerandomization and Randomization. The Prerandomization Phase will last up to 21 days and will consist of a Screening Period (Days -21 to -2) and a Baseline Period (Day -1). Following the Baseline Period, all eligible subjects will be randomized, in a double-blind manner, to receive E2006 or placebo for 15 nights during the Treatment Period (Days 1 to 15), then all subjects will receive placebo, in a single-blind manner, for 2 nights (Days 16 to 17) during the Rebound Insomnia Assessment Period (Days 16 to 18). Subjects will not receive any treatment during the Follow-up Period (Days 19 to 29). All subjects will come to the clinic for screening procedures. During the Screening Period, subjects will complete the Sleep Diary each day. Polysomnographic sleep will be measured during the Screening Period on 2 consecutive nights between Day -9 and Day -3. These 8-hour polysomnograms (PSGs) will start at the median habitual bedtime calculated from responses on the Sleep Diary completed 7 days immediately prior to the first PSG night. Subjects may leave the clinic between the screening/baseline PSG nights.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
E2006
E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Intervention: E2006
Placebo
E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Intervention: Placebo
Outcomes
Primary Outcomes
Probability of Having Utility Function Greater Than (>) 1 Based on Bayesian Analysis
Time Frame: Baseline up to Day 3
The utility of a dose was a function of both Sleep Efficiency (SE) and Karolinska Sleepiness Scale (KSS), constructed by specifying the 1-dimensional component for each outcome measure and then combining them multiplicatively. Sufficient utility was defined as a probability of having utility function \>1. Probability of having utility function \>1 at the end of study visit (full analysis) was reported.
Mean Change From Baseline in Karolinska Sleepiness Scale (KSS) Score at End of Treatment
Time Frame: 1 hour after morning wake time at Baseline and Days 15-16
The KSS was used to measure next-day residual effects at prespecified time points. The KSS was a 9-point scale on which the participant rated their sleepiness from 1 (extremely alert) to 9 (extremely sleepy/fighting sleep), where higher scores indicated an increase in sleepiness. The end of treatment score was calculated by the mean scores at the timepoint at 1 hour after morning wake time of Day 15 and 16.
Secondary Outcomes
- Potential Habituation Effect: Comparison Between Mean Change From Baseline in SE on Days 1-2 and Mean Change From Baseline in SE on Days 14-15(Baseline, Days 1-2, and Days 14-15)
- Potential Habituation Effect: Comparison Between Mean Change From Baseline in Latency to Persistent Sleep (LPS) on Days 1-2 and Mean Change From Baseline in LPS on Days 14-15(Baseline and Days 1-2, and Days 14-15)
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs(Baseline up to Day 30)
- Mean Change From Baseline in Latency to Persistent Sleep (LPS) After Dosing on Days 1-2 and Days 14-15(Baseline, Days 1-2, and Days 14-15)
- Percentage of Participants With Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)(TEAEs: Baseline up to Day 30, SAEs: Baseline up to 30 days after last dose of study drug (up to 47 days))
- Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 1-2 and Days 14-15(Baseline, Days 1-2, and Days 14-15)
- Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) After Dosing on Days 1-2 and Days 14-15(Baseline, Days 1-2, and Days 14-15)
- Potential Habituation Effect: Comparison Between Mean Change From Baseline in Wakefulness After Sleep Onset (WASO) on Days 1-2 and Mean Change From Baseline in WASO on Days 14-15(Baseline, Days 1-2, and Days 14-15)
- Number of Participants With Clinically Significant Change From Baseline in Clinical Laboratory Parameters(Baseline up to Day 30)
- Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECGs)(Baseline up to Day 30)
- Rebound Insomnia: Mean Change From Baseline in Sleep Efficiency (SE) After Dosing on Days 16-17(Baseline and Days 16-17)